Hong Kong Drug Approval: New System in 2026
- Hong Kong will begin independently reviewing and approving new drugs in phases, starting when its new regulatory agency commences operations, possibly by the end of 2026.
- the Department of Health unveiled plans Thursday to establish the drug regulatory authority.This initiative is central to Hong Kong's ambition to establish itself as an international hub for...
- Ronald Lam Man-kin, director of health, said the phased implementation of the primary evaluation approach is expected to bring more new drugs to the Hong Kong market.this new...
Hong Kong is set to revolutionize its pharmaceutical landscape! A new regulatory agency will independently approve new drugs in phases, beginning by late 2026. This strategic move aims to enhance the availability of vital medications within the city and solidify Hong Kong’s position as a hub for medical innovation. The Hong Kong Center for the Medical Products Regulation will lead this enterprising undertaking. This initiative, crucial for Hong Kong’s future, introduces a “primary evaluation” approach, streamlining drug approval based on clinical trial data. With the phased implementation, Hong Kong will play a larger role in the global pharmaceutical market. News Directory 3 provides complete updates. Discover what’s next for drug approval in hong Kong.
Hong Kong to independently Approve New Drugs by Late 2026
Updated June 26, 2025
Hong Kong will begin independently reviewing and approving new drugs in phases, starting when its new regulatory agency commences operations, possibly by the end of 2026. Health officials anticipate this move will lead to a greater availability of new medications in the city.
the Department of Health unveiled plans Thursday to establish the drug regulatory authority.This initiative is central to Hong Kong’s ambition to establish itself as an international hub for health and medical innovation. The Hong Kong Centre for the Medical Products Regulation is expected to be a leading international regulatory authority.
Dr. Ronald Lam Man-kin, director of health, said the phased implementation of the primary evaluation approach is expected to bring more new drugs to the Hong Kong market.this new approach will allow the city to expedite the drug approval process.
Chief Executive John Lee Ka-chiu initially proposed establishing an agency for “primary evaluation” drug approvals in his 2023 policy address. primary evaluation involves approving drugs based on their clinical trial data, without needing prior approval from other regulatory bodies.This new drug approval role is key to hong Kong’s future.
What’s next
The establishment of the Hong Kong Centre for the Medical Products Regulation will continue through 2026, with phased implementation of independent drug reviews expected to begin before the end of that year. This will allow Hong Kong to play a larger role in the global pharmaceutical market.